riociguat

Ligand id: 5257

Name: riociguat

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 138.07
Molecular weight 422.16
XLogP 2.1
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Riociguat is approved to treat persistent or recurrent chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. This drug was approved following assessment within the US FDA orphan and priority review process.
Mechanism Of Action and Pharmacodynamic Effects
Riociguat activates soluble guanylyl cyclase (sGC), a heterodimeric enzyme comprising α and β chains. The genes and proteins for the enzyme subunits are listed in this database, in the Soluble guanylyl cyclase family. sGC is a receptor for nitric oxide (NO), activation of which increases biosynthesis of cyclic GMP and this leads to vasodilation.
External links